Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 6:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Levalbuterol Clear all
Withdrawn Phase 1 Interventional

Airway Temperature

NCT02401074
View directory record Official record
Conditions
Asthma
Interventions
Segmental Bronchoprovocation with Allergen (SBP-Ag)
Biological
Lead sponsor
Lu Yuan Lee
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Albuterol Sulfate Extended-Release Tablets 8 mg and VoSpire® ER Tablets 8 mg

NCT00649779
View directory record Official record
Conditions
Healthy
Interventions
albuterol sulfate extended-release 8 mg tablets, VoSpire™ ER 8 mg tablets
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2008 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 3 Interventional

A Crossover Study in the Treatment of Patients With COPD

NCT00462540
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Formoterol Fumurate inhalation solution 20 mcg, Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
15
States / cities
San Diego, California • Denver, Colorado • Wheat Ridge, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2009 · Synced Sep 20, 2026, 6:30 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Advair HFA in Healthy and HAPE Predisposed Subjects

NCT06040268
View directory record Official record
Conditions
Altitude Edema
Interventions
Advair HFA, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

NCT01772368
View directory record Official record
Conditions
Asthma
Interventions
Fp MDPI, FS MDPI, Advair Diskus, Albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
10
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 3 Interventional

Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)

NCT00685126
View directory record Official record
Conditions
Reactive Airways Disease (RAD)
Interventions
Levalbuterol HCl Inhalation Solution, Albuterol HCl Inhalation Solution
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
Up to 48 Months
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
32
States / cities
Little Rock, Arkansas • Corona, California • Englewood, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)

NCT00821093
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Indacaterol 150 µg, Salmeterol 50 µg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
74
States / cities
Anniston, Alabama • Fairhope, Alabama • Jasper, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma

NCT02584257
View directory record Official record
Conditions
Mild Persistent Asthma
Interventions
methacholine chloride, placebo ProAir HFA, ProAir HFA, Lupin albuterol HFA MDI, placebo Lupin albuterol HFA MDI
Other · Drug
Lead sponsor
Lupin, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
17
States / cities
Huntington Beach, California • Mission Viejo, California • Rolling Hills Estates, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2020 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 1 Interventional Results available

Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma

NCT02260492
View directory record Official record
Conditions
Asthma
Interventions
OT329 (combination of fluticasone propionate and salmeterol xinafoate), Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate), Placebo
Drug
Lead sponsor
Oriel Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
47
States / cities
Goodyear, Arizona • Tempe, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 20, 2026, 6:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diagnosis of Exercise-induced Bronchospasm (EIB) and Asthma in National Collegiate Athletic Association (NCAA) Division I Athletes

NCT00752167
View directory record Official record
Conditions
Exercise Induced Bronchospasm, Asthma
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 11, 2016 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01323621
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg, Fluticasone Propionate 250mcg / salmeterol 50mcg, Double-dummy placebo, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Jasper, Alabama • Riverside, California • DeLand, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

NCT00588406
View directory record Official record
Conditions
Asthma
Interventions
Budesonide, albuterol, Ipratropium bromide, Prednisone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
East Meadow, New York • Queens, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Sep 20, 2026, 6:30 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

High Flow Nasal Cannula Rates in Pediatric Asthma

NCT06379607
View directory record Official record
Conditions
Pediatric Asthma
Interventions
"High Flow" High Flow Nasal Cannula, "Low Flow" High Flow Nasal Cannula
Device
Lead sponsor
University of Rochester
Other
Eligibility
2 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Different Doses of Indacaterol

NCT01079130
View directory record Official record
Conditions
Asthma
Interventions
Indacaterol, Salmeterol, Placebo to Indacaterol, Placebo to Salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
71
States / cities
Glendale, Arizona • Scottsdale, Arizona • Encinitas, California + 64 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2011 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease

NCT01391559
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
arformoterol, salmeterol
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
60 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 6, 2013 · Synced Sep 20, 2026, 6:30 PM EDT
Terminated Not applicable Interventional Results available

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

NCT00706446
View directory record Official record
Conditions
Asthma
Interventions
tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 3 Interventional

Study of Levalbuterol, Racemic Albuterol and Placebo in Subjects Twelve Years of Age and Older With Asthma

NCT00073827
View directory record Official record
Conditions
Asthma
Interventions
levalbuterol tartrate MDI, racemic albuterol MDI, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
63
States / cities
Homewood, Alabama • Mobile, Alabama • Corona, California + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2012 · Synced Sep 20, 2026, 6:30 PM EDT
Completed No phase listed Observational Results available

Sensor and Electronic Health Records (EHR) Integration Pilot Study

NCT03357341
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Mobile spirometer, Device sensor, Salbutamol, Activity monitor, electronic diary card, CAT, ACT
Device · Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 20, 2026, 6:30 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

NCT06052267
View directory record Official record
Conditions
Asthma
Interventions
TEV-56248, Albuterol sulfate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
4 Years and older
Enrollment
2,772 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
157
States / cities
Birmingham, Alabama • Dothan, Alabama • Paradise Valley, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia

NCT01987219
View directory record Official record
Conditions
Familial Dysautonomia
Interventions
Albuterol-sulphate, Ipratropium-bromide, placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
12 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

NCT02175771
View directory record Official record
Conditions
Persistent Asthma
Interventions
Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

NCT01772134
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Jasper, Alabama • Clearwater, Florida • Ormond Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 3 Interventional Results available

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00677807
View directory record Official record
Conditions
COPD
Interventions
Indacaterol, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
93
States / cities
Homewood, Alabama • Jasper, Alabama • Phoenix, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2011 · Synced Sep 20, 2026, 6:30 PM EDT
Completed Phase 2 Interventional

Confirmatory Dose Finding Study of 2 Dosages of CHF 4226 pMDI (Carmoterol) in Patients With COPD

NCT00640484
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
carmoterol (CHF 4226), placebo, salmeterol
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
40 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
15
States / cities
Gilbert, Arizona • Phoenix, Arizona • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2010 · Synced Sep 20, 2026, 6:30 PM EDT